Affini-T Therapeutics to Present AFNT-211 T Cell Product Attributes Targeting KRAS G12V at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

BOSTON & SEATTLE–(BUSINESS WIRE)–Affini-T Therapeutics to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Click here to view original post